The estrogen receptor test (ERT) is a laboratory test to determine whether cancer cells have estrogen receptors. This information can help establish how the cancer should be treated.
The test uses immunohistochemical techniques on the estrogen receptor (ER) tumor marker. Immunohistochemistry (IHC) methods involve the selective identification of antigen proteins by exploiting antigen-antibody relationships.
Previously, the ligand binding assay was used to determine ER activity. However, this method was limited because of the large quantities of fresh tissue needed for each assay. IHC serves as a more efficient method as this technique allows for the tissue morphology to be observed in a tumor-specific manner. This increases the practicability of this technique as in many cases, patients’ tissue samples are limited in the applications of biomarker analysis. Anti-estrogen receptor antibodies were among the first of biomarkers that introduced a semi-quantitative assessment of ER activity.
Today, ER analysis is one of many routinely performed immunohistochemical assays performed to classify the hormone receptor status and to serve as a means of insight into the determination of cancer prognosis and management.
Estrogen receptor test
The ER activity can be monitored using immunohistochemical methods in applications like tissue analysis for tumorigenesis. The activation of the ER through binding to the estrogen hormone stimulates mammary cell division, catalyzing cell division and DNA replication processes. This results in exponential multiplication the mutated genes, along with large amounts of genotoxic waste, which in turn highly increase the chances of malignant cell formation and the likelihood of tumor formation.
Estrogen receptor types
There are two main types of estrogen receptors: estrogen receptor alpha (ERα) also known as NR3B1, and estrogen receptor beta (ER-β) also known as NR3A2. Both are nuclear receptors activated by the sex hormone estrogen and encoded by the ESR1 (Estrogen Receptor 1) gene. The estrogen signaling can be stimulated or inhibited selectively. This depends upon the equilibrium of these two receptor types in target organs.
These two ER types are encoded by different genes located on separate chromosomes and have different functions. ERα is mostly active in the mammary gland and uterus, and aids in the regulation of skeletal homeostasis and metabolism. ER-β on the other hand, plays a more prominent role in the central nervous and immune systems functional mechanisms.
Immunohistochemical assessment
The ERT immunohistochemical assessment is a semi-quantitative method used to predict the likelihood of success to anti-estrogen therapy in breast carcinoma. ER-positive breast carcinomas are likely to respond to various endocrine treatments. Therefore, monitoring ER activity can be essential in disease and treatment progression.
Various target antibodies may be used in the IHC assessment of the ER. Typically, the antibody used for this experiment is the anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Antibody. Employing SP1 allows for detecting estrogen receptor (ER) antigens in sections of the fixed patient samples. In junction with light microscopy, the approximate ER activity can be estimated using the level of staining of the cell's components. The anti-ER (SP1) antibody targets the ER alpha protein (ERα) located in the nucleus of ER-positive normal and neoplastic cells. The anti-ER (SP1) antibody's response is a useful indication of the progression, management, and prediction of therapy outcome of breast cancer. These antibodies are commercially available from 3 commonly used auto strain vendors- Dako, Leica, and Ventana. In a study by Kornaga et al, all behaved similarly in the semi-quantitative analysis of breast cancer biopsy samples.
In a study in 2002, 6 breast carcinoma cases were received, characterized, and analyzed through the ERT IHC assessment. The level of known ER activity was classified (negative, low, medium, and high) and selected for observation. After embedment in a paraffin block, the samples were stained using a hematoxylin and eosin staining (H & E staining) system. The IHC analysis was then performed the same day using anti-ER monoclonal antibodies, and resulted in a consistently strong correlation in the carcinoma samples with ER activity. In contrast, the level of ER activity increased, while the IHC response increased respectively.